Computer-aided Drug Discovery and Development Market
Number of pages: 100 | Report Format: PDF | Published date: April 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.18 billion |
|
Revenue Forecast in 2031 |
US$ 8.32 billion |
|
CAGR |
11.35% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Therapeutics Area, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global computer-aided drug discovery and development market was valued at US$ 3.18 billion in 2022 and is expected to register a revenue CAGR of 11.35% to reach US$ 8.32 billion by 2031.
Computer-aided Drug Discovery and Development Market Fundamentals
Computer-Aided Drug Design (CADD) techniques have become important drug discovery and development tools. Apart from academics, pharmaceutical and biotechnology firms use intelligent software to aid in identifying or optimizing bioactive substances. Several medications are discovered and optimized at various phases utilizing CADD technology. Aliskiren, Boceprevir, Captopril, Dorzolamide, Nolatrexed, Oseltamivir, Rupintrivir, Saquinavir, and Zanamivir are some such medications. The quantitative structure-activity relationship (QSAR) has been an example for decades.
The dependability of data (accurate homolog/analog series and activity ranges) and the statistics used to verify and create the equation are critical components of a solid QSAR equation. A pharmacophore is a set of molecular properties (for example, hydrogen bond acceptor/donor, aromatic, hydrophobic, ionizable, and so on) that are important in the molecular recognition of ligands by a macromolecule. The binding site of the target biological macromolecule is used to generate the characteristics necessary for ligand interaction with crucial amino acid residues. A pharmacophore can be used as a 3D query to uncover drug candidates for further optimization and testing from a database of millions (or even billions) of molecules (virtual screening). In contrast, molecular docking typically screens just thousands of compounds.
[86786]
Computer-aided Drug Discovery and Development Market Dynamics
Even though the new coronavirus pandemic severely affected various businesses, the computer-aided drug development market achieved sizable revenue growth during this time. Additionally, the computer-aided drug development market has grown rapidly due to increasing R&D activity among scientists, researchers, and biotechnological and biopharmaceutical businesses to limit the spread of the coronavirus illness. The increasing transmutation rate of coronavirus has prompted scientists worldwide to develop a viable therapy or medicine against this lethal virus. As a result, the importance of research and medication discovery has increased, propelling the market revenue share.
The global computer-aided drug discovery market is also expanding rapidly, owing mostly to the increased use of artificial intelligence in drug discovery for drug screening, chemical synthesis, Poly pharmacology, and studying the three-dimensional structure of molecules. Furthermore, artificial intelligence has created several potentials for enterprises to enter the market and employ AI technology with computer-aided medication discovery.
Furthermore, the increasing demand for personalized treatments and an increased need for early and precise disease diagnosis also aid market growth. One of the factors driving the growth of the computer-aided drug discovery market revenue is the growing desire for personalized medications. Personalized medications are meant to target an individual’s distinct genetic composition. Compared to standard treatments, these medications are more effective and have fewer adverse effects. Personalized medications are becoming increasingly important in treating illnesses such as cancer, Alzheimer’s disease, and diabetes.
Another key reason driving the growth of the computer-aided drug discovery market revenue is the increasing requirement for early and precise illness diagnosis. Early illness detection is critical since it allows for prompt treatment and minimizes the probability of the disease spreading. By giving accurate and extensive information about the condition, computer-aided drug development aids in the early and exact detection of diseases.
Moreover, computer-aided drug discovery technology is further augmented by recent developing technologies, such as machine learning (ML) and artificial intelligence (AI), which drive research programs in the biotechnological and pharmaceutical sectors. These are significant market growth-boosting variables. Drug discovery businesses extensively use computational tools such as computer-aided drug discovery. This software technology is augmented by some of the most recent developing technologies, such as machine learning (ML) and artificial intelligence (AI), which drive research programs in the biotechnological and pharmaceutical sectors. The increasing speed of drug discovery research has created several possibilities for significant firms to invest in CADD technology.
However, since computer-aided drug discovery is a relatively new technology, many healthcare professionals are either unaware of it or lack the understanding of its utilization of it for drug development. It is also a very sophisticated method that takes advanced talents to operate. It takes a long time for people to grasp the usage of the software. These issues are projected to suppress future market expansion. Aside from that, computer-aided drug design needs a large library of bimolecular structures for analyzing the drug’s interaction with ligand molecules. Other problems, such as a lack of standardization for testing and validation of results, an accurate scoring function, and a lack of a high-quality database for biomolecules, are projected to impede the future growth of computer-aided drug discovery and development market revenue.
Computer-aided Drug Discovery and Development Market Ecosystem
The global computer-aided drug discovery and development are analyzed from four perspectives: type, therapeutics area, end user, and region.
Computer-aided Drug Discovery and Development Market by Type
[86766]
Based on type, the global computer-aided drug discovery and development market can be further segmented into structure-based drug design, ligand-based drug design, and sequence-based approach.
Structure-based drug design accounts for the largest revenue share in the global market. Structure-based drug design employs three-dimensional (3D) structural information from proteins to create novel physiologically active compounds. Thus, the major initial phase of SBDD is identifying a target molecule and characterizing its structure. The discovered target might be an enzyme linked to a condition of interest. Based on binding affinity measurements, candidate drugs are identified that inhibit the activity of the target. As a result, SBDD uses knowledge about a biological target to identify possible novel medications. As a result, SBDD represents a significant development in computational approaches utilized in biophysics, medicinal chemistry, statistics, biochemistry, and other domains. Scientific progress has resulted in a plethora of strategies for predicting protein structures. These cutting-edge technologies enable the structure of a large number of proteins to be determined using cryo-electron microscopy (EM), nuclear magnetic resonance (NMR), X-ray crystallography, and computational approaches such as homology modeling and molecular dynamic (MD) simulation. Thus, these factors are responsible for the dominance of the structure-based drug design segment revenue share.
Similarly, the ligand-based drug design (LBDD) segment is expected to rise with consistent revenue growth from 2023 to 2031. LBDD provides a generic technique for understanding links between compound/ligand structure, physicochemical features, and biological activity. This method is used when 3D structural information for a target protein is lacking. The existing knowledge of ligands and their biological activity is employed in this procedure to produce new potential therapeutic candidates. Over half of the authorized medications target membrane proteins (for which 3D structures are frequently unavailable, such as GPCR), and LBDD is commonly employed in pharmaceutical research. It is predicated on the premise that substances with comparable structural properties have similar biological actions and interact/inhibit the same target molecules.
Computer-aided Drug Discovery and Development Market by Therapeutic Area
Based on the therapeutic area, the global computer-aided drug discovery and development market can be further segmented into oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others.
Due to rapidly growing cases of different cancer among people, the oncology segment dominates the global market. Additionally, continuously rising incidences of relapsed/refractory cancer. Hence, increased demand for effective cancer treatments, driving the growth of the oncology segment in the CADD market. Cancer is a complex disease with multiple subtypes and various mechanisms of progression. This complexity makes it difficult to develop effective treatments using traditional drug discovery methods. CADD tools can help identify novel targets and compounds that effectively target cancer cells. The availability of genomic data has led to the development of personalized medicine in oncology. CADD tools can help analyze this data and identify drug targets specific to an individual’s cancer, leading to the development of personalized therapies. The pharmaceutical industry has invested heavily in oncology research and development, developing a large pipeline of oncology drugs. CADD tools play a critical role in drug discovery, helping identify novel targets and compounds that can be developed into effective drugs.
Computer-aided Drug Discovery and Development Market by End User
Based on the end user, the global computer-aided drug discovery and development market is segmented into pharmaceutical & biotechnology companies and research institutes.
The pharmaceutical and biotechnology companies segment accounts for the largest revenue share in the global market. Pharmaceutical and biotechnology companies invest significant resources in drug discovery, including CADD tools. These companies have the financial resources to invest in state-of-the-art technology and the expertise to interpret the data generated by CADD tools. Pharmaceutical and biotechnology companies are highly focused on developing innovative drugs to treat various diseases. CADD tools enable these companies to identify novel drug targets and compounds that may not have been identified using traditional drug discovery methods. Pharmaceutical and biotechnology companies have extensive pipelines of drug candidates that require screening and optimization using CADD tools. These pipelines may include drugs for various diseases, including cancer, autoimmune disorders, and infectious diseases. The pharmaceutical industry is highly competitive; companies must protect their intellectual property to maintain a competitive edge. CADD tools can help identify novel drug targets and compounds that can be patented, protecting the company’s intellectual property.
Computer-aided Drug Discovery and Development Market by Region
Based on the region, the global computer-aided drug discovery and development market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominates the global market with the largest revenue share. The large market revenue growth in this region is attributed to the large patient base for cancer cases and neurological diseases such as Alzheimer, Epilepsy, and Parkinson’s disease. Additionally, it enhanced market players’ engagement in developing noble treatments and therapy, with rapid growth in strategic collaborations, partnerships, and acquisitions. Moreover, well-developed healthcare infrastructure and rapid launch of new and improvised drugs. Thus, these factors all together encourage the growth of the market revenue in North America.
Computer-aided Drug Discovery and Development Market Competitive Landscape
The prominent players operating in the global computer-aided drug discovery and development market are:
Computer-aided Drug Discovery and Development Market Strategic Developments
The expected size of the global computer-aided drug discovery and development market will be US$ 8.37 billion in 2031.
The factors restraining the optimal growth of the global computer-aided drug discovery and development market are limited knowledge of the usage of CADD and the lack of well-skilled professionals.
The global computer-aided drug discovery and development market is expected to register a revenue CAGR of 11.35% during the forecast period from 2023 to 2031.
The global computer-aided drug discovery market is expanding rapidly, owing mostly to the increased use of artificial intelligence in drug discovery for drug screening, chemical synthesis, Poly pharmacology, and studying the three-dimensional structure of molecules. Furthermore, artificial intelligence has created several potentials for enterprises to enter the market and employ AI technology with computer-aided drug discovery.
Europe accounts for the second-largest revenue share in the global computer-aided drug discovery and development market.
*Insights on financial performance are subject to the availability of information in the public domain